BG-570 is under clinical development by SL Bigen and currently in Phase I for Tuberculosis. According to GlobalData, Phase I drugs for Tuberculosis have an 88% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how BG-570’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
BG-570 overview
BG-570 is under development for the prevention of multidrug-resistance tuberculosis (MDR-TB). It is a DNA vaccine.
SL Bigen overview
SL Bigen a research-based bio-genetic engineering company that develops and commercializes next-generation immunotherapies. SL Bigen develops stem cell lines designed to produce disease-specific therapeutic genes and also multi-engineered natural killer cell lines expressing fourth generation chimeric antigen receptors. The company’s manufacturing unit for the research and development of cell-based gene therapy is comprised of QC laboratory, process development room, and storage facility. SL Bigen offers its services through CAR-NK (chimeric antigen receptor-directed natural killer) and eMSC (expressing mesenchymal stem cells) programs. SL Bigen is headquartered in Incheon, South Korea.
For a complete picture of BG-570’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
